Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ACTengine® IMA203CD8 GEN2 (PRAME) in Uterine Cancer. The expected timing is based on the latest available company guidance and may change.
05/30/26:- Ph1 NCT03686124 uterine cancer data included in gynecologic cohort; durability follow-up update planned H2 2026. 07/17/26:- ESMO 2026 Phase 1 IMA203CD8 results abstract Oct 19; oral Oct 23, 2026. 08/18/26:- Phase 1 gynecologic cancer activity was updated. Multi-tumor data will be presented at ESMO 2026.
Verification
Confirm timing and program details against the company announcement or filing.